Cancer BiologyCancer ResearchPeer-reviewed
Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast Cancer
Daniel Ortega-Álvarez, David Tébar-García, Marta Casado-Peláez…·Verónica Rodilla
This study identifies BC-markers in TNBC, links them to poor prognosis and dasatinib sensitivity, suggesting TAGLN as a predictive biomarker for targeted therapy.